Elotuzumab
Looking up MedlinePlus…
From MedlinePlus, U.S. National Library of Medicine
SLAMF7-directed Immunostimulatory Antibody
Dosing in kidney impairment
This label has no separate kidney-impairment dosing section. Check warnings and clinical pharmacology in the full label.
Preparation and administration
Prepare this dose
Your numbers for elotuzumab. Take vial strength, diluent, and limits from the label below.
Enter a dose to see draw volume, final concentration, and rates.
Administration Administer the entire EMPLICITI infusion with an infusion set and a sterile, nonpyrogenic, low-protein-binding filter (with a pore size of 0.2 to 1.2 micrometer) using an automated infusion pump. Initiate EMPLICITI infusion at a rate of 0.5 mL per minute for 10 mg/kg dose. The infusion rate may be increased in a stepwise fashion as described in Table 3 if no infusion reactions develop.
The maximum infusion rate should not exceed 5 mL per minute. [See table below.] 30 min 0.5 mL/min 0-30 min 3 mL/min 30-60 min 1 mL/min 30 min or more 4 mL/min 5 mL/min 60 min or more 2 mL/min - - Initiate EMPLICITI infusion rate at 3 mL per minute for 20 mg/kg dose. The infusion rate may be increased in a stepwise fashion as described in Table 4 if no infusion reactions develop.
The maximum infusion rate should not exceed 5 mL per minute. Patients who have escalated to 5 mL/min at 10 mg/kg dose must decrease the rate to 3 mL/min at the first infusion at 20 mg/kg. [See table below.] Adjust the infusion rate following a Grade 2 or higher infusion reaction [see Dosage and Administration ] . Do not mix EMPLICITI with, or administer as an infusion with, other medicinal products.
No physical or biochemical compatibility studies have been conducted to evaluate the coadministration of EMPLICITI with other agents.
Reconstitution and Preparation Calculation of Dose
Calculate the dose (mg) and determine the number of vials needed for the 10 mg/kg and 20 mg/kg dosage based on patient weight.
Determine the volume of sterile water for injection (SWFI) needed for reconstitution as shown in Table 5. [See table below.] 400 mg vial 17 mL 16 mL* 25 mg/mL Reconstitution
Aseptically reconstitute each EMPLICITI vial with a syringe of adequate size and a less than or equal to 18-gauge needle (e.g., 17-gauge). A slight back pressure may be experienced during administration of the Sterile Water for Injection, USP, which is considered normal.
Hold the vial upright and swirl the solution by rotating the vial to dissolve the lyophilized cake. Invert the vial a few times in order to dissolve any powder that may be present on top of the vial or the stopper. Avoid vigorous agitation. DO NOT SHAKE. The lyophilized powder should dissolve in less than 10 minutes.
After the remaining solids are completely dissolved, allow the reconstituted solution to stand for 5 to 10 minutes. The reconstituted preparation results in a colorless to slightly yellow, clear to slightly opalescent solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Discard the solution if any particulate matter or discoloration is observed. Dilution
Once the reconstitution is completed, withdraw the necessary volume for the calculated dose from each vial, up to a maximum of 16 mL from 400 mg vial and 12 mL from 300 mg vial.
Further dilute with either 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP, into an infusion bag made of polyvinyl chloride or polyolefin. The final infusion concentration should range between 1 mg/mL and 6 mg/mL.
The volume of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP should be adjusted so as not to exceed 5 mL/kg of patient weight at any given dose of EMPLICITI. Complete the EMPLICITI infusion within 24 hours of reconstitution of the EMPLICITI lyophilized powder. If not used immediately, the infusion solution may be stored under refrigeration conditions: 2°C to 8°C (36°F-46°F) and protected from light for up to 24 hours (a maximum of 8 hours of the total 24 hours can be at room temperature, 20°C to 25°C [68°F-77°F], and room light).
| Cycle | 28-Day Cycles 1 and 2 | 28-Day Cycles 3+ | ||||||
|---|---|---|---|---|---|---|---|---|
| * Premedicate with the following 45 to 90 minutes prior to EMPLICITI infusion: 8 mg intravenous dexamethasone, H1 blocker: diphenhydramine (25 to 50 mg orally or intravenously) or equivalent; H2 blocker: ranitidine (50 mg intravenously) or equivalent; acetaminophen (650 to 1000 mg orally). † Oral dexamethasone (28 mg) taken between 3 and 24 hours before EMPLICITI infusion. ** Intravenous dexamethasone 45-90 minutes before EMPLICITI infusion. | ||||||||
| Day of Cycle | 1 | 8 | 15 | 22 | 1 | 8 | 15 | 22 |
| Premedication* | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
| EMPLICITI (mg/kg) intravenously | 10 | 10 | 10 | 10 | 10 | 10 | ||
| Lenalidomide (25 mg) orally | Days 1-21 | Days 1-21 | ||||||
| Dexamethasone† (mg) orally | 28 | 28 | 28 | 28 | 28 | 40 | 28 | 40 |
| Dexamethasone** (mg) intravenously | 8 | 8 | 8 | 8 | 8 | 8 | ||
| Day of Cycle | 1 | 8 | 15 | 22 | 1 | 8 | 15 | 22 |
| Cycle | 28-Day Cycles 1 and 2 | 28-Day Cycles 3+ | ||||||
|---|---|---|---|---|---|---|---|---|
| * Premedicate with the following 45 to 90 minutes prior to EMPLICITI infusion: 8 mg intravenous dexamethasone, H1 blocker: diphenhydramine (25 to 50 mg orally or intravenously) or equivalent; H2 blocker: ranitidine (50 mg intravenously) or equivalent; acetaminophen (650 to 1000 mg orally). † Oral dexamethasone taken between 3 and 24 hours before EMPLICITI infusion. ** Intravenous dexamethasone 45-90 minutes before EMPLICITI infusion. | ||||||||
| Day of Cycle | 1 | 8 | 15 | 22 | 1 | 8 | 15 | 22 |
| Premedication* | ✓ | ✓ | ✓ | ✓ | ✓ | |||
| EMPLICITI (mg/kg) intravenously | 10 | 10 | 10 | 10 | 20 | |||
| Pomalidomide (4 mg) orally | Days 1-21 | Days 1-21 | ||||||
| Dexamethasone† (mg) orally ≤75 years old | 28 | 28 | 28 | 28 | 28 | 40 | 40 | 40 |
| Dexamethasone† (mg) orally >75 years old | 8 | 8 | 8 | 8 | 8 | 20 | 20 | 20 |
| Dexamethasone** (mg) intravenously | 8 | 8 | 8 | 8 | 8 | |||
| Cycle 1, Dose 1 | Cycle 1, Dose 2 | Cycle 1, Dose 3 and 4 and All Subsequent Cycles | ||
|---|---|---|---|---|
| Time Interval | Rate | Time Interval | Rate | Rate |
| 0-30 min | 0.5 mL/min | 0-30 min | 3 mL/min | |
| 30-60 min | 1 mL/min | 30 min or more | 4 mL/min | 5 mL/min |
| 60 min or more | 2 mL/min | - | - | |
Drug interactions
Check elotuzumab against a medication listLabel text (3 paragraphs)
7 DRUG INTERACTIONS
7.1 Drug Interactions For important drug interactions involving lenalidomide, pomalidomide and dexamethasone, refer to their respective prescribing information.
7.2 Laboratory Test Interference EMPLICITI may be detected in the SPEP and serum immunofixation assays of myeloma patients and could interfere with correct response classification. A small peak in the early gamma region on SPEP that is IgGƙ on serum immunofixation may potentially be attributed to EMPLICITI, particularly in patients whose endogenous myeloma protein is IgA, IgM, IgD, or lambda light chain restricted. This interference can impact the determination of complete response and possibly relapse from complete response in patients with IgG kappa myeloma protein [see Warnings and Precautions (5.5) ].
Contraindications
None. None (4)
Pregnancy and lactation
Pregnancy
8.1 Pregnancy Risk Summary There are no available data on EMPLICITI use in pregnant women to inform a drug associated risk of major birth defects and miscarriage. Animal reproduction studies have not been conducted with elotuzumab. EMPLICITI is administered in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone. Lenalidomide and pomalidomide can cause embryo-fetal harm and are contraindicated for use in pregnancy. Refer to the lenalidomide, pomalidomide and dexamethasone prescribing information for additional information. Lenalidomide and pomalidomide are only available through a REMS program.
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
For breastfeeding, also see LactMed (National Library of Medicine), which summarizes milk levels and infant effects.
Supply and cost
Drug shortage status
Recalls (last 24 months)
Therapeutic equivalence (Orange Book)
Price ladder
Not the price at the counterThese are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.